Product Description
Adalimumab injection is used to treat the symptoms and prevent the progression of active rheumatoid arthritis and ankylosing spondylitis. It is used in children 2 years of age and older for juvenile idiopathic arthritis.
Mechanisms of Action: TNF Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Morocco | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Abbott Laboratories
Company Location: ABBOTT PARK IL 60064-3500
Company CEO: Robert B. Ford
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Belgium, Bulgaria, Canada, China, Czech Republic, Estonia, France, Germany, Italy, Japan, Mexico, New Zealand, Poland, Puerto Rico, Russia, Slovakia, Spain, Switzerland, Taiwan, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 19
Highest Development Phases
Phase 3: Arthritis, Juvenile|Arthritis, Psoriatic|Arthritis, Rheumatoid|Colitis, Ulcerative|Psoriasis|Spondylitis, Ankylosing
Phase 1: Arthritis, Infectious|Behcet Syndrome|COVID-19|Crohn Disease|Healthy Volunteers|Hidradenitis Suppurativa|Spondyloarthritis|Uveitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| KnaPsAck | P3 |
Recruiting |
Arthritis, Psoriatic|Arthritis, Juvenile |
2026-09-01 |
|
| M10-870 | P3 |
Unknown Status |
Colitis, Ulcerative |
2025-05-14 |
|
| MABPS-3/2020 | P3 |
Recruiting |
Psoriasis |
2025-03-01 |
|
| SOLOMON-I | P1 |
Recruiting |
Healthy Volunteers |
2024-11-01 |